Clinical Trials
9
Active:8
Completed:1
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)AXIS 2: AX200 for the Treatment of Ischemic Stroke
Phase 2
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- Biological: Filgrastim
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- Sygnis Bioscience GmbH & Co KG
- Target Recruit Count
- 328
- Registration Number
- NCT00927836
- Locations
- 🇦🇹
Landes-Nervenklinik Wagner-Jauregg, Linz, Austria
🇦🇹AHK Linz, Linz, Austria
🇦🇹Wilhelminenspital, Wien, Austria
News
No news found